title: Mechlorethamine, vincristine, melphalan and prednisone (MOMP) for the treatment of relapsed lymphoma in dogs.
abstract: Eighty-eight dogs with relapsed lymphoma were treated with the MOMP (mechlorethamine, vincristine, melphalan and prednisone) protocol on a 28-day treatment cycle. The overall response rate (ORR) to the MOMP protocol was 51.1% for a median of 56 days (range 7-858 days). Twelve percent of dogs experienced a complete response for a median of 81 days (range 42-274 days) and 38.6% experienced a partial response for a median of 49 days (range 7-858 days). Dogs with T-cell lymphoma had an ORR of 55% for a median of 60 days (range 49-858 days) while those with B-cell lymphoma had an ORR of 57% for a median of 81 days (range 7-274 days) (P = 0.783). The overall survival time for all dogs was 183 days (range 17-974 days). Fifty-four percent of dogs experienced toxicity with the majority classified as grade I. The MOMP protocol seems well-tolerated and is an option for dogs with relapsed lymphoma.
authors.affiliation: Comparative Oncology Program, Department of Clinical Sciences, Auburn University, College of Veterinary Medicine, Auburn, AL, USA.
authors.forename: A R
authors.initials: AR
authors.lastname: Back
authors.affiliation: Comparative Oncology Program, Department of Clinical Sciences, Auburn University, College of Veterinary Medicine, Auburn, AL, USA.
authors.forename: S E
authors.initials: SE
authors.lastname: Schleis
authors.affiliation: Comparative Oncology Program, Department of Small Animal Medicine, University of Tennessee, College of Veterinary Medicine, Knoxville, TN, USA.
authors.forename: O A
authors.initials: OA
authors.lastname: Smrkovski
authors.affiliation: Comparative Oncology Program, Department of Small Animal Medicine, University of Tennessee, College of Veterinary Medicine, Knoxville, TN, USA.
authors.forename: J
authors.initials: J
authors.lastname: Lee
authors.affiliation: Comparative Oncology Program, Department of Clinical Sciences, Auburn University, College of Veterinary Medicine, Auburn, AL, USA.
authors.forename: A N
authors.initials: AN
authors.lastname: Smith
authors.affiliation: Animal Emergency Critical Care and Referral Center, Knoxville, TN, USA.
authors.forename: J C
authors.initials: JC
authors.lastname: Phillips
mesh_terms: D000818:Animals; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000008:administration & dosage / Q000627:therapeutic use*; D004283:Dog Diseases / Q000188:drug therapy* / Q000401:mortality; D004285:Dogs; D005260:Female; D008223:Lymphoma / Q000188:drug therapy / Q000401:mortality / Q000662:veterinary*; D016393:Lymphoma, B-Cell / Q000188:drug therapy / Q000401:mortality / Q000662:veterinary; D016399:Lymphoma, T-Cell / Q000188:drug therapy / Q000401:mortality / Q000662:veterinary; D008297:Male; D008466:Mechlorethamine / Q000008:administration & dosage* / Q000627:therapeutic use; D008558:Melphalan / Q000008:administration & dosage* / Q000627:therapeutic use; D011241:Prednisone / Q000008:administration & dosage* / Q000627:therapeutic use; D012008:Recurrence; D016019:Survival Analysis; D014750:Vincristine / Q000008:administration & dosage* / Q000627:therapeutic use
chemical_list: D008466:Mechlorethamine; D014750:Vincristine; D008558:Melphalan; D011241:Prednisone
keywords: canine; chemotherapy; lymphoma; melphalan; rescue